Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation

Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8

Iyengar, 2018, Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial, JAMA Oncol, 4, 10.1001/jamaoncol.2017.3501

Ruers, 2017, Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial, J Natl Cancer Inst, 109, 10.1093/jnci/djx015

Gomez, 2019, Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study, J Clin Oncol, 37, 1558, 10.1200/JCO.19.00201

Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5

Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853

Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3

Pitroda, 2019, Integrated molecular and clinical staging defines the spectrum of metastatic cancer, Nat Rev Clin Oncol, 16, 581, 10.1038/s41571-019-0220-6

Lussier, 2011, MicroRNA expression characterizes oligometastasis(es), PLoS One, 6, 10.1371/journal.pone.0028650

Lussier, 2012, Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs, PLoS One, 7, 10.1371/journal.pone.0050141

Pitroda, 2018, Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis, Nat Commun, 9

Dhondt, 2018, Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time, World J Urol

deSouza, 2019, A risk-based approach to identifying oligometastatic disease on imaging, Int J Cancer, 144, 422, 10.1002/ijc.31793

Rieber, 2017, Influence of institutional experience and technological advances on outcome of stereotactic body radiation therapy for oligometastatic lung disease, Int J Radiat Oncol Biol Phys, 98, 511, 10.1016/j.ijrobp.2016.09.026

Samim, 2017, The diagnostic performance of 18F-FDG PET/CT, CT and MRI in the treatment evaluation of ablation therapy for colorectal liver metastases: a systematic review and meta-analysis, Surg Oncol, 26, 37, 10.1016/j.suronc.2016.12.006

Lecouvet, 2018, Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group, Lancet Oncol, 19, e534, 10.1016/S1470-2045(18)30571-0

deSouza, 2018, Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group, Eur J Cancer, 91, 153, 10.1016/j.ejca.2017.12.012

Planchard, 2018, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 29, 192, 10.1093/annonc/mdy275

Dingemans, 2019, Definition of synchronous oligo-metastatic non-small cell lung cancer—a consensus report, J Thorac Oncol, 10.1016/j.jtho.2019.07.025

Ashworth, 2013, Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature, Lung Cancer, 82, 197, 10.1016/j.lungcan.2013.07.026

Goldstraw, 2016, The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer, J Thorac Oncol, 11, 39, 10.1016/j.jtho.2015.09.009

Fong, 1999, Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases, Ann Surg, 230, 309, 10.1097/00000658-199909000-00004

Fode, 2015, Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases, Radiother Oncol, 114, 155, 10.1016/j.radonc.2014.12.003

Tanadini-Lang, 2017, Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease, Radiother Oncol, 123, 182, 10.1016/j.radonc.2017.01.003

Hong, 2018, Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis, PLoS One, 13, 10.1371/journal.pone.0195149

Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, J Clin Epidemiol, 62, 1006, 10.1016/j.jclinepi.2009.06.005

Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. Practical Assessment, Research & Evaluation 12: 1–8.

Niibe, 2010, Oligometastases and oligo-recurrence: the new era of cancer therapy, Jpn J Clin Oncol, 40, 107, 10.1093/jjco/hyp167

Palma, 2014, The oligometastatic state—separating truth from wishful thinking, Nat Rev Clin Oncol, 11, 549, 10.1038/nrclinonc.2014.96

Reyes, 2015, The biology and treatment of oligometastatic cancer, Oncotarget, 6, 8491, 10.18632/oncotarget.3455

Correa, 2016, Stereotactic body radiotherapy for oligometastasis: opportunities for biology to guide clinical management, Cancer J, 22, 247, 10.1097/PPO.0000000000000202

Patel, 2019, The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?, Clin Oncol (R Coll Radiol), 10.1016/j.clon.2019.05.015

Laurie, 2019, Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer, Curr Oncol, 26, e81, 10.3747/co.26.4116

Milano, 2010, Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ, Am J Clin Oncol, 33, 157, 10.1097/COC.0b013e3181979238

Decaestecker, 2014, Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence, Radiat Oncol, 9, 135, 10.1186/1748-717X-9-135

Butte, 2015, Recurrence after partial hepatectomy for metastatic colorectal cancer: potentially curative role of salvage repeat resection, Ann Surg Oncol, 22, 2761, 10.1245/s10434-015-4370-1

Kim, 2010, Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites, Cancer Res Treat, 42, 217, 10.4143/crt.2010.42.4.217

Mekenkamp, 2010, Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases, Br J Cancer, 103, 159, 10.1038/sj.bjc.6605737

Tsai, 2007, Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis, Ann Surg Oncol, 14, 786, 10.1245/s10434-006-9215-5

Ashworth, 2014, An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer, Clin Lung Cancer, 15, 346, 10.1016/j.cllc.2014.04.003

Fleckenstein, 2016, Long-term outcomes in radically treated synchronous vs metachronous oligometastatic non-small-cell lung cancer, BMC Cancer, 16, 348, 10.1186/s12885-016-2379-x

Neeff, 2009, Outcome after resection of hepatic and pulmonary metastases of colorectal cancer, J Gastrointest Surg, 13, 1813, 10.1007/s11605-009-0960-1

Shukuya, 2011, Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure, Lung Cancer, 74, 457, 10.1016/j.lungcan.2011.04.007

Weickhardt, 2012, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, 7, 1807, 10.1097/JTO.0b013e3182745948

Yu, 2013, Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors, J Thorac Oncol, 8, 346, 10.1097/JTO.0b013e31827e1f83

Lohaus, 2019, Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease?, Eur Urol, 75, 548, 10.1016/j.eururo.2018.11.050

Schmid, 2019, Patterns of progression on osimertinib in EGFR T790M positive NSCLC: a Swiss cohort study, Lung Cancer, 130, 149, 10.1016/j.lungcan.2019.02.020

Iyengar, 2014, Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer, J Clin Oncol, 32, 3824, 10.1200/JCO.2014.56.7412

Heitmann, 2018, Perspectives on oligometastasis: challenges and opportunities, J Thorac Dis, 10, 113, 10.21037/jtd.2017.12.77

Scher, 2000, Clinical states in prostate cancer: toward a dynamic model of disease progression, Urology, 55, 323, 10.1016/S0090-4295(99)00471-9

Klement, 2018, Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy, Radiother Oncol, 127, 246, 10.1016/j.radonc.2018.02.016